Pantoprazole Azevedos (Pantoprazole)

Pantoprazole Azevedos is a proton pump inhibitor used to manage conditions caused by excess gastric acid.

• Gastroesophageal reflux disease (GERD): reduces acid exposure and relieves heartburn and regurgitation.
• Erosive esophagitis: promotes healing of acid‑induced esophageal lesions.
• Peptic ulcer disease: supports ulcer resolution by lowering gastric acidity.
• Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors.

• Pantoprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid production, it markedly reduces basal and stimulated gastric acid secretion, thereby increasing gastric pH and allowing mucosal healing in acid‑related disorders.

Adverse reactions may occur with any medication. The following lists have been observed in clinical practice.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools that may be transient.
• Nausea: feeling of stomach upset.
• Abdominal pain: discomfort in the upper abdomen.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Elevated liver enzymes: signs of hepatic stress.
• Hypomagnesemia: low magnesium levels causing muscle cramps or arrhythmias.
• Stevens‑Johnson syndrome: rare skin blistering disorder.
• Anaphylaxis: life‑threatening systemic hypersensitivity.

Before initiating therapy, consider the following safety measures.

• Renal or hepatic impairment: assess function and adjust monitoring.
• Elderly patients: use cautiously due to increased sensitivity.
• Magnesium monitoring: check serum levels during prolonged use.
• Discontinuation: avoid abrupt cessation after long‑term therapy to prevent rebound acid hypersecretion.
• Drug interaction review: evaluate concomitant medications for potential conflicts.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole may affect the pharmacokinetics of several drugs. Review the categories below.

Major Interactions (Avoid)

• Ketoconazole: reduced absorption due to increased gastric pH.
• Atazanavir: decreased plasma concentrations, compromising antiviral effect.
• Nelfinavir: impaired bioavailability, leading to sub‑therapeutic levels.
• Clopidogrel: decreased activation, potentially reducing antiplatelet efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring closer coagulation monitoring.
• Digoxin: higher serum concentrations may occur, necessitating dose adjustment.
• Methotrexate: reduced renal clearance can raise toxicity risk.
• HIV protease inhibitors (e.g., ritonavir): altered plasma levels, monitor therapeutic response.
• Iron salts: decreased iron absorption, consider timing separation.